Astellas Pips Janssen To Post With English Funding For New Prostate Cancer Indication
Executive Summary
NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.